Allurion Technologies (ALUR) AI Stock Analysis

• Market Cap: $16.95M
• Dividend Yield: N/A
• Average Volume (3M): 77.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.55
• Revenue Growth: -58.15%
• EPS Growth: 60.43%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 49
• Industry: Medical - Devices
• EPS (TTM): -2.37
• Shares Outstanding: 7,762,681
• 10 Day Avg. Volume: 87,963
• 30 Day Avg. Volume: 77,729
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 2.10
• Enterprise Value/Revenue: 1.78
• Enterprise Value/Gross Profit: 2.89
• Enterprise Value/Ebitda: -1.19
• 1Y Price Target: $13.33
• Price Target Upside: 511.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 38 Underperform
• Price Target: $2.00 ▼(-8.26% Downside)

Allurion Technologies is currently facing significant financial difficulties, with declining revenues, persistent losses, and high leverage. The technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. While the earnings call suggests potential for future growth through strategic pivots, the current financial and market conditions present substantial risks.

Positive Factors

Market Expansion

The Allurion Balloon has been cleared to resume sales in France, which historically accounted for ~15% of sales, potentially providing a meaningful tailwind to ALUR's growth trajectory.

Product Efficacy

The study succeeded in the responder rate co-primary endpoint, with 58% of Allurion balloon patients losing more than 5% of their total body weight at 48 weeks, a statistically significant result.

Regulatory Approval

ALUR will use the Audacity results to support the FDA approval of the Allurion balloon, with a potential mid-2025 submission for the technology's PMA application.

Negative Factors

Market Performance

There was a 32% year-over-year decline in 4Q'24 revenue, primarily due to a temporary suspension of sales in France and macroeconomic headwinds affecting re-order rates.

Price Target

The price target for Allurion Technologies, Inc. has been significantly lowered to $6 from the previous $16, reflecting a recent contraction in small-cap valuations.

Revenue Performance

Revenue was $3.4M, which fell short of the $5.2M consensus.

Allurion Technologies Business Overview & Revenue Model

Company Description

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

How the Company Makes Money

Allurion Technologies generates revenue primarily through the sale of its Allurion Balloon and related services. The company partners with healthcare providers and clinics to distribute its product to patients seeking weight loss solutions. Revenue is driven by the sale of the balloon itself, as well as ancillary services such as digital monitoring and coaching, which are part of the company's holistic weight loss program. Strategic partnerships with medical professionals and clinics are critical to Allurion's business model, as they facilitate access to a broader patient base and enhance the credibility and reach of its weight management solutions.

Allurion Technologies Financial Statement Overview

Summary

Allurion Technologies faces significant financial challenges, characterized by declining revenue, persistent losses, high leverage, and negative cash flows. Strategic changes are necessary to stabilize and improve financial health in a highly competitive medical devices industry.

Income Statement

Allurion Technologies has experienced significant revenue fluctuations, with a notable decline from 2022 to 2023. The company faces negative profit margins, including a negative gross profit margin in 2024, and sustained losses in net income, EBIT, and EBITDA, indicating ongoing challenges in achieving profitability.

Balance Sheet

The balance sheet reveals a concerning financial structure, with negative stockholders' equity and high leverage as indicated by a high debt-to-equity ratio. The equity ratio is negative, reflecting a risk of insolvency, compounded by the decline in assets and insufficient equity to cover liabilities.

Cash Flow

Cash flow analysis shows persistently negative operating and free cash flows, signaling liquidity issues. The company has relied heavily on financing activities to fund operations, which is unsustainable in the long term without improved financial performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.92M	32.11M	53.47M	64.21M	38.24M	0.00
Gross Profit	12.30M	21.50M	41.50M	50.73M	29.19M	0.00
EBITDA	-29.83M	-22.17M	-69.03M	-32.28M	-8.01M	-5.17K
Net Income	-31.53M	-26.15M	-80.61M	-37.74M	-12.39M	-5.17K
Balance Sheet
Total Assets	28.17M	32.81M	71.71M	51.37M	39.35M	329.96K
Cash, Cash Equivalents and Short-Term Investments	12.72M	15.38M	38.04M	7.68M	25.84M	47.09K
Total Debt	30.52M	37.92M	41.86M	59.53M	26.14M	170.00K
Total Liabilities	92.14M	110.79M	142.20M	122.81M	73.64M	310.13K
Stockholders Equity	-63.98M	-77.98M	-70.49M	-71.44M	-34.28M	19.83K
Cash Flow
Free Cash Flow	-41.89M	-42.91M	-65.59M	-48.53M	-15.24M	―
Operating Cash Flow	-41.82M	-42.30M	-63.98M	-46.98M	-14.33M	―
Investing Cash Flow	-72.00K	-611.00K	-1.61M	-1.55M	-912.00K	0.00
Financing Cash Flow	35.31M	20.21M	95.99M	30.54M	28.95M	47.13K

Allurion Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.18
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 2.18 is below the 20-day moving average (MA) of 2.48, below the 50-day MA of 2.64, and below the 200-day MA of 4.59, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 36.22 is Neutral, neither overbought nor oversold. The STOCH value of 34.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.

Allurion Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.83B	-0.15	-40.10%	2.29%	21.46%	-2.01%
PAVM	51 Neutral	$8.98M	0.45	-499.57%	―	-73.36%	―
ADGM	47 Neutral	$19.53M	―	-329.16%	―	15.00%	71.57%
LFWD	43 Neutral	$9.89M	―	-114.90%	―	4.96%	-13.09%
ALUR	38 Underperform	$16.95M	―	38.80%	―	-58.15%	60.43%
IINN	35 Underperform	$30.23M	―	-196.69%	―	―	―
MOVE	23 Underperform	$4.83M	―	-439.23%	―	―	56.73%

Allurion Technologies Corporate Events

Allurion Technologies Reports Q2 Results and Strategic Pivot

On August 13, 2025, Allurion Technologies announced its second quarter financial results, revealing a strategic pivot towards low-dose GLP-1 combination therapy and U.S. market entry. The company reported a revenue of $3.4 million for the quarter, reflecting a decrease due to distributor transitions and reduced sales in certain markets. Despite this, Allurion is optimistic about long-term growth through new strategic partnerships and a focus on next-generation R&D, aiming to establish a new standard of care in obesity management.

Allurion Technologies Announces Strategic Restructuring Plan

On August 5, 2025, Allurion Technologies announced a strategic restructuring plan to focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry. This plan involves a significant workforce reduction and aims to enhance distribution and R&D capabilities, including a potential joint development of a novel GLP-1 drug-eluting balloon. The company is transitioning to distribution partners with access to physician networks and has observed growth in clinics adopting the combination therapy. Despite short-term disruptions, Allurion expects long-term growth and improved financial performance.